Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ: LEXX )

1.320 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio
Via Investor Brand Network
Lexaria Bioscience Corp. to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... 
Via Benzinga
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
- DehydraTECH-CBD also being evaluated in three other human clinical studies - Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1, designed to evaluate whether its DehydraTECH(TM)-CBD (“... 
Via Benzinga
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures
Lexaria Bioscience Corp (NASDAQ: LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure... 
Via Benzinga
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
- New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses
Via CannabisNewsWire
Lexaria Bioscience Corp.'s DehydraTECH(TM) Addresses the Needs of Medical THC Users
Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver... 
Via Benzinga
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
Via CannabisNewsWire
New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology as an Alternative to Smoking and Vaping
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Impacting the Pharmaceutical Industry
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Impacting the Pharmaceutical Industry
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
Lexaria's Technology Proven to Deliver Oral THC More Effectively
- DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Outcome of NIC-A21-1 Study Using DehydraTECH(TM)-Nicotine Pouches
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug Use Technology Nets Zacks Research Coverage
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Outstanding Results of Oral Nicotine Study
Via Investor Brand Network
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.